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515Cardiovascular Data Registry (NCDR) Implantable
Cardioverter-Deﬁbrillator registry. They found that
among patients with left bundle branch block (LBBB),
mortality is lower in women than men, but this
is not the case for patients with non-LBBB QRS
morphologies, regardless of the QRSd. In both sexes,
longer QRSd in the LBBB cohorts was associated with
lower mortality for both men and women; women
with LBBB and QRSd of 140 to 159 ms had a lower
mortality than men with similar QRS morphology and
QRSd, although this was not the case in patients with
QRSd of $150 ms.
Women have shorter QRSd than men, and this has
been often attributed to their smaller ventricles (1);
however, there is another mechanism producing
additional shortening of the QRSd, which is
dependent on QRS amplitude (QRSa) and leads to an
apparent shortening of the QRSd (2–4). Accordingly,
if QRSd is corrected for the corresponding QRSa in
the patients of the NCDR, the results might be
different than reported herein. In addition,
attributing the mortality improvement in patients
receiving CRT only to the QRS morphology (i.e.,
LBBB) and the QRSd underemphasizes the issue of
the effectiveness of the CRT, based on the appropriate
positioning of the left ventricular (LV) epicardial pacing
leads and the timing of the stimulation of the LV and
right ventricle. Regarding the later, perhaps data on the
CRT biventricular pacing-based QRSd (5), if available in
the NCDR, may enhance the value of the authors’
contribution.*John E. Madias, MD
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in terms of response to cardiac resynchronization
therapy (CRT). QRS amplitude could be important but
is not available in the National Cardiovascular Data
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Don’t Drop Aspirin Just YetWe read with interest the review article from Dewilde
et al. (1) who nicely summarize the available evidence
on triple antithrombotic therapy in patients with atrial
ﬁbrillation (AF) undergoing coronary stenting. The
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516authors conclude that the combination of vitamin K
antagonists (VKA) and clopidogrel may serve as a
valuable alternative to a triple antithrombotic
regimen also including aspirin, based on the results
of 1 small randomized controlled trial and a large
nationwide registry (2,3).
In a recent joint consensus document frommultiple
European Associations, endorsed by the Heart Rhythm
Society and Asia-Paciﬁc Heart Rhythm Society, dual
therapy consisting of VKA and clopidogrel “may” (i.e.,
Class IIb) or even “should” (i.e., Class IIa) be consid-
ered in patients with stable coronary artery disease
undergoing stenting with variable lengths and
strengths of recommendation depending on indi-
vidual stroke (i.e., CHA2DS2-VASc score ¼ 1 or $2) and
bleeding (i.e., HAS-BLED ¼ 0 to 2 or $3) risks (4). We
underscore that aspirin should not be dropped in
patients at low bleeding risk on long-term VKA
therapy in the context of an acute coronary syndrome
(ACS)—with or without stenting, and for at least the
ﬁrst 6 months—because: 1) the beneﬁt of dual
antiplatelet therapy in ACS patients is established (5);
and 2) the WOEST (What is the Optimal antiplatElet
and anticoagulant therapy in patients with oral
anticoagulation and coronary StenTing) trial included
only a minority (w25%) of patients with an ACS (2).
Other limitations of the WOEST trial are also evident,
including the prolonged period (12 months) of triple
therapy and the endpoint driven by minor bleeds
(with major bleeds not different between triple and
dual therapy) (4).
In the Danish registry, where only ACS patients
where included by study design, the adjusted risk of
all-cause mortality compared with aspirin mono-
therapy was numerically, albeit not signiﬁcantly,
lower with triple antithrombotic therapy (i.e., hazard
ratio: 1.04) than with a dual therapy regimen of VKA
and clopidogrel (i.e., hazard ratio 1.22), whereas the
risk of fatal and nonfatal bleeding was signiﬁcantly
increased with both regimens (3). As far as the
duration of triple antithrombotic therapy is
concerned, the joint European document points out
that the period where maximum antithrombotic
protection should be given (in patients at low or
moderate bleeding risk) corresponds to the ﬁrst 6
months after the onset of an ACS and/or a second-
generation drug-eluting stent implantation (4).
This has been recently found to be consistent
with the 2014 European guidelines for myocardial
revascularization (5) and the newly presented ISAR-
TRIPLE (Intracoronary Stenting and Antithrombotic
Regimen—Testing of a six-week versus a six-month
clopidogrel treatment Regimen In Patients with
concomitant aspirin and oraL anticoagulant therapyfollowing drug-Eluting stenting) study (presented at
Transcatheter Cardiovascular Therapeutics, September
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Don’t Drop Aspirin Just YetWe thank Drs. Capodanno and Lip for their interest in
and valuable comments on our recent review (1) on
triple therapy for atrial ﬁbrillation (AF) and
percutaneous coronary intervention (PCI).
The conclusion of our review was that it might be a
reasonable option to treat with a combination of
vitamin K antagonists (VKA) and clopidogrel, which
